艾迪注射液配合TP方案治疗晚期非小细胞肺癌的临床研究

A Clinical Study on paclitaxel and cisplation chemotherapy combined with Aidi injection in treatment of advanced non-small cell lung cancer

目的比较TP化疗方案联合艾迪注射液与单纯TP方案对晚期非小细胞肺癌的疗效和毒副反应。方法A组应用Taxol＋DDP化疗同时加用艾迪注射液50mL，1次/d，21d为1周期，连用2周期为1疗程；B组单用Taxol＋DDP化疗。结果A组有效率为48．0％（24／50），B组有效率41．3％（19/46），两组近期疗效无显著性差异（P〉0．05）。A组的Ⅲ＋Ⅳ白细胞抑制毒性及消化道反应均低于B组（P〈0．05）。结论初步研究结果提示：TP方案联合艾迪注射液治疗晚期非小细胞肺癌，能降低化疗毒副反应．

Objective To compare the therapeutic effect and adverse reaction in paclitaxel （TAXOL） and cisplation （DDP） of chemotherapy combined with Aidi injection with those of chemotherapy alone in patients with non-small cell lung cancer. Methods In Group A, in the same of TP chemotherapy ,50ml of Aidi injection was given intravenously on days 1-21, each cycle consisting for 21 days with at least 2 cycles administered for one course. There was only TP chemotherapy in Group B. Results The effective rates in Group A and Group B were 48.0% （24/50） and 41.3 % （19/46） respectively. There was no statistically significant difference of overall response rate between two groups （P〉0.05）. The major side effects were leukopenia and gastrointestinal reaction.Ⅲ＋Ⅳ leukocyte suppression and gastrointestinal reaction were lower in Group A than that in Group B （P〈0.05）. Conclusions The primary research shows that TP chemotherapy combined with Aidi injection can reduce the adverse reaction of chemotherapy in patient s with advanced non-small cell lung cancer.